Ayalew Tefferi

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Esfandyari Tuba; Tefferi Ayalew; Szmidt Anna; Alain Tommy; Zwolak Pawel; Lasho Terra; Lee Patrick W; Farassati Faris
Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.
Tefferi Ayalew; Vardiman James W
Myelodysplastic syndromes.
Tefferi Ayalew; Skoda Radek; Vardiman James W
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ayalew Tefferi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Esfandyari Tuba; Tefferi Ayalew; Szmidt Anna; Alain Tommy; Zwolak Pawel; Lasho Terra; Lee Patrick W; Farassati Faris
Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.
Molecular oncology 2009;3(5-6):464-8.
2009: Tefferi Ayalew; Vardiman James W
Myelodysplastic syndromes.
The New England journal of medicine 2009;361(19):1872-85.
2009: Tefferi Ayalew; Skoda Radek; Vardiman James W
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
Nature reviews. Clinical oncology 2009;6(11):627-37.
2009: Pardanani Animesh; Tefferi Ayalew; Litzow Mark R; Zent Clive; Hogan William J; McClure Rebecca F; Viswanatha David
Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.
Blood 2009;114(16):3502-3.
2009: Chee Cheng E; Warrington Kenneth J; Tefferi Ayalew
Chronic natural killer-cell lymphocytosis successfully treated with alemtuzumab.
Blood 2009;114(16):3500-2.
2009: Tefferi Ayalew; Passamonti Francesco
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
American journal of hematology 2009;84(10):629-30.
2009: Pardanani Animesh; Lim Ken-Hong; Lasho Terra L; Finke Christy; McClure Rebecca F; Li Chin-Yang; Tefferi Ayalew
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
Blood 2009;114(18):3769-72.
2009: Tefferi Ayalew
Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center.
European journal of haematology 2009;83(4):290-1.
2009: Tefferi Ayalew; Lim Ken-Hong; Levine Ross
Mutation in TET2 in myeloid cancers.
The New England journal of medicine 2009;361(11):1117; author reply 1117-8.
2009: Tefferi Ayalew; Verstovsek Srdan; Barosi Giovanni; Passamonti Francesco; Roboz Gail J; Gisslinger Heinz; Paquette Ronald L; Cervantes Francisco; Rivera Candido E; Deeg H Joachim; Thiele Juergen; Kvasnicka Hans M; Vardiman James W; Zhang Yanming; Bekele B Nebiyou; Mesa Ruben A; Gale Robert P; Kantarjian Hagop M
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4563-9.
2009: Mesa Ruben A; Tefferi Ayalew
Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Expert opinion on emerging drugs 2009;14(3):471-9.
2009: Tefferi Ayalew; Thiele Juergen; Vardiman James W
The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Cancer 2009;115(17):3842-7.
2009: Mesa Ruben A; Schwager Susan; Radia Deepti; Cheville Andrea; Hussein Kebede; Niblack Joyce; Pardanani Animesh D; Steensma David P; Litzow Mark R; Rivera Candido E; Camoriano John; Verstovsek Srdan; Sloan Jeffrey; Harrison Claire; Kantarjian Hagop; Tefferi Ayalew
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Leukemia research 2009;33(9):1199-203.
2009: Huang Jocelin; Tefferi Ayalew
Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.
European journal of haematology 2009;83(2):154-5.
2009: Hussein Kebede; Tefferi Ayalew
Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
Leukemia research 2009;33(8):e132-3.
2009: Pardanani A; Lasho T; Smith G; Burns C J; Fantino E; Tefferi A
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(8):1441-5.
2009: Patnaik Mrinal M; Tefferi Ayalew
Molecular diagnosis of myeloproliferative neoplasms.
Expert review of molecular diagnostics 2009;9(5):481-92.
2009: Vardiman James W; Thiele Jüergen; Arber Daniel A; Brunning Richard D; Borowitz Michael J; Porwit Anna; Harris Nancy Lee; Le Beau Michelle M; Hellström-Lindberg Eva; Tefferi Ayalew; Bloomfield Clara D
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Blood 2009;114(5):937-51.
2009: Gangat Naseema; Tefferi Ayalew; Thanarajasingam Gita; Patnaik Mrinal; Schwager Susan; Ketterling Rhett; Wolanskyj Alexandra P
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
European journal of haematology 2009;83(1):17-21.
2009: Wiktor Anne E; Hanson Curtis A; Hodnefield Janice M; Hussein Kebede; Tefferi Ayalew; Van Dyke Daniel L
Circulating blasts or myeloid precursor cells in peripheral blood can predict success of cytogenetic analysis.
Leukemia research 2009;33(7):e75-6.
2009: Lim Ken-Hong; Tefferi Ayalew; Lasho Terra L; Finke Christy; Patnaik Mrinal; Butterfield Joseph H; McClure Rebecca F; Li Chin-Yang; Pardanani Animesh
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Blood 2009;113(23):5727-36.
2009: Gery Sigal; Cao Qi; Gueller Saskia; Xing Hongtao; Tefferi Ayalew; Koeffler H Phillip
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
Journal of leukocyte biology 2009;85(6):957-65.
2009: Fink Stephanie R; Belongie Kimberly J; Paternoster Sarah F; Smoley Stephanie A; Pardanani Animesh D; Tefferi Ayalew; Van Dyke Daniel L; Ketterling Rhett P
Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations.
Leukemia research 2009;33(6):843-6.
2009: Tefferi Ayalew; Mesa Ruben A; Pardanani Animesh; Hussein Kebede; Schwager Susan; Hanson Curtis A; Steensma David P
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
American journal of hematology 2009;84(5):265-7.
2009: Vannucchi Alessandro M; Guglielmelli Paola; Tefferi Ayalew
Advances in understanding and management of myeloproliferative neoplasms.
CA: a cancer journal for clinicians 2009;59(3):171-91.
2009: Patnaik M M; Tefferi A
The complete evaluation of erythrocytosis: congenital and acquired.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):834-44.
2009: Tefferi A; Pardanani A; Lim K-H; Abdel-Wahab O; Lasho T L; Patel J; Gangat N; Finke C M; Schwager S; Mullally A; Li C-Y; Hanson C A; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland D G; Levine R L
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):905-11.
2009: Tefferi A; Levine R L; Lim K-H; Abdel-Wahab O; Lasho T L; Patel J; Finke C M; Mullally A; Li C-Y; Pardanani A; Gilliland D G
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(5):900-4.
2009: Gangat Naseema; Wolanskyj Alexandra P; Schwager Susan; Tefferi Ayalew
Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies.
European journal of haematology 2009;82(5):350-3.
2009: Hussein Kebede; Van Dyke Daniel L; Tefferi Ayalew
Conventional cytogenetics in myelofibrosis: literature review and discussion.
European journal of haematology 2009;82(5):329-38.
2009: Tefferi Ayalew; Sirhan Shireen; Sun Yi; Lasho Terra; Finke Christy M; Weisberger James; Bale Sherri; Compton John; LeDuc Charles A; Pardanani Animesh; Thorland Erik C; Shevchenko Yuriy; Grodman Marc; Chung Wendy K
Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis.
Leukemia research 2009;33(5):662-4.
2009: Hussein Kebede; Huang Jocelin; Lasho Terra; Pardanani Animesh; Mesa Ruben A; Williamson Cynthia M; Ketterling Rhett P; Hanson Curtis A; Van Dyke Daniel L; Tefferi Ayalew
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
European journal of haematology 2009;82(4):255-9.
2009: Siragusa Sergio; Passamonti Francesco; Cervantes Francisco; Tefferi Ayalew
Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.
American journal of hematology 2009;84(3):140-3.
2009: Cervantes Francisco; Dupriez Brigitte; Pereira Arturo; Passamonti Francesco; Reilly John T; Morra Enrica; Vannucchi Alessandro M; Mesa Ruben A; Demory Jean-Loup; Barosi Giovanni; Rumi Elisa; Tefferi Ayalew
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Blood 2009;113(13):2895-901.
2009: Tefferi Ayalew
JAK2V617F: more than a clonal marker?
Leukemia & lymphoma 2009;50(2):154-5.
2009: Tefferi Ayalew
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Journal of cellular and molecular medicine 2009;13(2):215-37.
2009: Mesa Ruben A; Hanson Curtis A; Ketterling Rhett P; Schwager Susan; Knudson Ryan A; Tefferi Ayalew
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Blood 2009;113(5):1200-1.
2009: Tefferi Ayalew; Levine Ross L; Kantarjian Hagop
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(1 Suppl):114-9.
2009: Verstovsek Srdan; Tefferi Ayalew; Kantarjian Hagop; Manshouri Taghi; Luthra Raja; Pardanani Animesh; Quintás-Cardama Alfonso; Ravandi Farhad; Ault Pat; Bueso-Ramos Carlos; Cortes Jorge E
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):368-73.
2009: Tefferi Ayalew
Myeloproliferative neoplasms: thrombophilic clonal stem cell diseases.
Cancer treatment and research 2009;148():157-79.
2008: Tefferi Ayalew
Epigenetic alterations and anti-epigenetic therapy in myelofibrosis.
Leukemia & lymphoma 2008;49(12):2231-2.
2008: Tefferi Ayalew
Is "cure" essential in the treatment of cancer?
Mayo Clinic proceedings. Mayo Clinic 2008;83(12):1413-4.
2008: Santana-Davila Rafael; Tefferi Ayalew; Holtan Shernan G; Ketterling Rhett P; Dewald Gordon W; Knudson Ryan A; Steensma David P; Chen Dong; Hoyer James D; Hanson Curtis A
Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Leukemia research 2008;32(12):1927-30.
2008: Steensma David P; Tefferi Ayalew
Incremental gains and a long road ahead in MDS.
Oncology (Williston Park, N.Y.) 2008;22(12):1352, 1358, 1360.
2008: Tefferi Ayalew
Platelet count in essential thrombocythemia: the more the better?
Blood 2008;112(8):3526; author reply 3526-7.
2008: Hussein Kebede; Ketterling Rhett P; Dewald Gordon W; Van Dyke Daniel L; Mesa Ruben; Hanson Curtis A; Tefferi Ayalew
Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies.
Leukemia research 2008;32(10):1597-600.
2008: Malhotra Pankaj; Hogan William J; Litzow Mark R; Elliott Michelle A; Gastineau Dennis A; Ansell Stephen M; Dispenzieri Angela; Gertz Morie A; Hayman Suzanne R; Inwards David J; Lacy Martha Q; Micallef Ivana N; Porrata Luis F; Tefferi Ayalew
Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years.
Leukemia & lymphoma 2008;49(9):1724-30.
2008: Tefferi Ayalew
Idiopathic erythrocytosis: a non-entity?
Leukemia & lymphoma 2008;49(9):1649-50.
2008: Tefferi Ayalew
The need for adequate coverage of oncology topics in internal medicine journals.
Mayo Clinic proceedings. Mayo Clinic 2008;83(9):980-2.
2008: Holtan Shernan G; Santana-Davila Rafael; Dewald Gordon W; Khetterling Rhett P; Knudson Ryan A; Hoyer James D; Chen Dong; Hanson Curtis A; Porrata Luis; Tefferi Ayalew; Steensma David P
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
American journal of hematology 2008;83(9):708-13.
2008: Chee Cheng E; Steensma David P; Wu Wenting; Hanson Curtis A; Tefferi Ayalew
Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts.
American journal of hematology 2008;83(8):611-3.
2008: Tefferi Ayalew
Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
Leukemia & lymphoma 2008;49(7):1225-7.
2008: Gangat Naseema; Tefferi Ayalew
Pharmacotherapy of essential thrombocythemia.
Expert opinion on pharmacotherapy 2008;9(10):1679-85.
2008: Verstovsek Srdan; Tefferi Ayalew; Cortes Jorge; O'Brien Susan; Garcia-Manero Guillermo; Pardanani Animesh; Akin Cem; Faderl Stefan; Manshouri Taghi; Thomas Deborah; Kantarjian Hagop
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3906-15.
2008: Tefferi Ayalew
Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
American journal of hematology 2008;83(6):491-7.
2008: Huang Jocelin; Li Chin-Yang; Mesa Ruben A; Wu Wentling; Hanson Curtis A; Pardanani Animesh; Tefferi Ayalew
Risk factors for leukemic transformation in patients with primary myelofibrosis.
Cancer 2008;112(12):2726-32.
2008: Gangat Naseema; Strand Jacob J; Lasho Terra L; Li Chin-Yang; Pardanani Animesh; Tefferi Ayalew
Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis.
American journal of hematology 2008;83(6):451-3.
2008: Sirhan Shireen; Lasho Terra L; Hanson Curtis A; Mesa Ruben A; Pardanani Animesh; Tefferi Ayalew
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
American journal of hematology 2008;83(5):363-5.
2008: Tefferi Ayalew; Gangat Naseema; Wolanskyj Alexandra P; Schwager Susan; Pardanani Animesh; Lasho Terra L; Mesa Ruben; McClure Rebecca F; Li Chin-Yang; Hanson Curtis A
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
European journal of haematology 2008;80(5):386-90.
2008: Geron Ifat; Abrahamsson Annelie E; Barroga Charlene F; Kavalerchik Edward; Gotlib Jason; Hood John D; Durocher Jeffrey; Mak Chi Ching; Noronha Glenn; Soll Richard M; Tefferi Ayalew; Kaushansky Ken; Jamieson Catriona H M
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Cancer cell 2008;13(4):321-30.
2008: Wernig Gerlinde; Kharas Michael G; Okabe Rachel; Moore Sandra A; Leeman Dena S; Cullen Dana E; Gozo Maricel; McDowell Elizabeth P; Levine Ross L; Doukas John; Mak Chi Ching; Noronha Glenn; Martin Michael; Ko Yon D; Lee Benjamin H; Soll Richard M; Tefferi Ayalew; Hood John D; Gilliland D Gary
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Cancer cell 2008;13(4):311-20.
2008: Pardanani Animesh; Lasho Terra L; Hussein Kebede; Schwager Susan M; Finke Cristy M; Pruthi Rajiv K; Tefferi Ayalew
JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Mayo Clinic proceedings. Mayo Clinic 2008;83(4):457-9.
2008: Tefferi A; Lasho T L; Huang J; Finke C; Mesa R A; Li C Y; Wu W; Hanson C A; Pardanani A
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):756-61.
2008: Hussein Kebede; Ketterling Rhett P; Hulshizer Rachael L; Kuffel Daniel G; Wiktor Anne E; Hanson Curtis A; Tefferi Ayalew; Van Dyke Daniel L
Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis.
European journal of haematology 2008;80(4):318-21.
2008: Tefferi Ayalew
JAK and MPL mutations in myeloid malignancies.
Leukemia & lymphoma 2008;49(3):388-97.
2008: Palmer Shanique R; Tefferi Ayalew; Hanson Curtis A; Steensma David P
Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts.
British journal of haematology 2008;140(6):722-5.
2008: Tefferi Ayalew; Kantarjian Hagop
Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
American journal of hematology 2008;83(3):175-7.
2008: Gangat Naseema; Strand Jacob; Lasho Terra L; Finke Christy M; Knudson Ryan A; Pardanani Animesh; Li Chin-Yang; Ketterling Rhett P; Tefferi Ayalew
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.
European journal of haematology 2008;80(3):197-200.
2008: Pardanani Animesh; Fridley Brooke L; Lasho Terra L; Gilliland D Gary; Tefferi Ayalew
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.
Blood 2008;111(5):2785-9.
2008: Santana-Davila Rafael; Holtan Shernan G; Dewald Gordon W; Ketterling Rhett P; Knudson Ryan A; Hanson Curtis A; Steensma David P; Tefferi Ayalew
Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.
Leukemia research 2008;32(3):407-11.
2008: Steensma David P; Tefferi Ayalew
JAK2 V617F and ringed sideroblasts: not necessarily RARS-T.
Blood 2008;111(3):1748.
2008: Barosi G; Mesa R A; Thiele J; Cervantes F; Campbell P J; Verstovsek S; Dupriez B; Levine R L; Passamonti F; Gotlib J; Reilly J T; Vannucchi A M; Hanson C A; Solberg L A; Orazi A; Tefferi A;
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(2):437-8.
2008: Knoll Bettina; Rea David J; Szoztek Jason; Nagorney David S; Tefferi Ayalew; Mesa Ruben A
Extramedullary hematopoiesis.
American journal of hematology 2008;83(2):171.
2008: Tefferi Ayalew; Verstovsek Srdan; Pardanani Animesh
How we diagnose and treat WHO-defined systemic mastocytosis in adults.
Haematologica 2008;93(1):6-9.
2008: Tefferi A
The history of myeloproliferative disorders: before and after Dameshek.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(1):3-13.
2008: Tefferi A; Vardiman J W
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(1):14-22.
2008: Ho Ching-Liang; Kito Hirohito; Squillace Diane L; Lasho Terra L; Tefferi Ayalew
Clinical correlates of serum pro-major basic protein in a spectrum of eosinophilic disorders and myelofibrosis.
Acta haematologica 2008;120(3):158-64.
2008: Lim Ken-Hong; Pardanani Animesh; Tefferi Ayalew
KIT and mastocytosis.
Acta haematologica 2008;119(4):194-8.
2008: Tefferi Ayalew
Mutant molecules of interest in myeloproliferative neoplasms: introduction.
Acta haematologica 2008;119(4):192-3.
2008: Tefferi Ayalew
Primary myelofibrosis.
Cancer treatment and research 2008;142():29-49.
2007: Elliott Michelle A; Litzow Mark R; Letendre Louis L; Wolf Robert C; Hanson Curtis A; Tefferi Ayalew; Tallman Martin S
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.
Blood 2007;110(13):4172-4.
2007: Tefferi Ayalew
JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Cancer journal (Sudbury, Mass.) 2007;13(6):366-71.
2007: Tefferi Ayalew
Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?
Mayo Clinic proceedings. Mayo Clinic 2007;82(11):1316-8.
2007: Landstrom Andrew P; Knudson Ryan A; Dewald Gordon W; Ketterling Rhett P; Tefferi Ayalew
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.
Leukemia & lymphoma 2007;48(11):2137-40.
2007: Steensma David P; Porcher Julie C; Hanson Curtis A; Lathrop Cynthia L; Hoyer James D; Lasho Terra A; Tefferi Ayalew; Higgs Douglas R
Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders.
British journal of haematology 2007;139(3):439-42.
2007: Elliott M A; Verstovsek S; Dingli D; Schwager S M; Mesa R A; Li C Y; Tefferi A
Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.
Leukemia research 2007;31(11):1503-9.
2007: Pardanani A; Lasho T L; Finke C; Markovic S N; Tefferi A
Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(10):2206-7.
2007: Ho Ching-Liang; Lasho Terra L; Butterfield Joseph H; Tefferi Ayalew
Global cytokine analysis in myeloproliferative disorders.
Leukemia research 2007;31(10):1389-92.
2007: Levine Ross L; Pardanani Animesh; Tefferi Ayalew; Gilliland D Gary
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Nature reviews. Cancer 2007;7(9):673-83.
2007: Pardanani A; Lasho T L; Finke C; Hanson C A; Tefferi A
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):1960-3.
2007: Mesa R A; Camoriano J K; Geyer S M; Wu W; Kaufmann S H; Rivera C E; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li C Y; Tefferi A
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):1964-70.
2007: Pardanani Animesh; Lasho Terra L; Finke Christy; Mesa Ruben A; Hogan William J; Ketterling Rhett P; Gilliland Dwight Gary; Tefferi Ayalew
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
Stem cells (Dayton, Ohio) 2007;25(9):2358-62.
2007: Tefferi A; Strand J J; Lasho T L; Knudson R A; Finke C M; Gangat N; Pardanani A; Hanson C A; Ketterling R P
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):2074-5.
2007: Zou Ying S; Fink Stephanie R; Stockero Kimberly J; Paternoster Sarah F; Smoley Stephanie A; Tun Han W; Reeder Craig B; Tefferi Ayalew; Dewald Gordon W
Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
Leukemia research 2007;31(9):1185-9.
2007: Patnaik Mrinal M; Tefferi Ayalew; Pardanani Animesh
Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders.
Current cancer drug targets 2007;7(5):492-503.
2007: Steensma David P; Tefferi Ayalew
Anemia in the elderly: how should we define it, when does it matter, and what can be done?
Mayo Clinic proceedings. Mayo Clinic 2007;82(8):958-66.
2007: Gangat Naseema; Strand Jacob; Li Chin-Yang; Wu Wenting; Pardanani Animesh; Tefferi Ayalew
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.
British journal of haematology 2007;138(3):354-8.
2007: Pardanani A; Hood J; Lasho T; Levine R L; Martin M B; Noronha G; Finke C; Mak C C; Mesa R; Zhu H; Soll R; Gilliland D G; Tefferi A
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(8):1658-68.
2007: Tefferi Ayalew; Thiele Juergen; Orazi Attilio; Kvasnicka Hans Michael; Barbui Tiziano; Hanson Curtis A; Barosi Giovanni; Verstovsek Srdan; Birgegard Gunnar; Mesa Ruben; Reilly John T; Gisslinger Heinz; Vannucchi Alessandro M; Cervantes Francisco; Finazzi Guido; Hoffman Ronald; Gilliland D Gary; Bloomfield Clara D; Vardiman James W
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Blood 2007;110(4):1092-7.
2007: Pardanani A; Lasho T L; Schwager S; Finke C; Hussein K; Pruthi R K; Tefferi A
JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(8):1828-9.
2007: Kamal Arif H; Tefferi Ayalew; Pruthi Rajiv K
How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults.
Mayo Clinic proceedings. Mayo Clinic 2007;82(7):864-73.
2007: Pan J; Quintás-Cardama A; Manshouri T; Giles F J; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(7):1395-404.
2007: Tefferi Ayalew; Elliott Michelle
Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
Seminars in thrombosis and hemostasis 2007;33(4):313-20.
2007: Kittur Jaya; Knudson Ryan A; Lasho Terra L; Finke Christy M; Gangat Naseema; Wolanskyj Alexandra P; Li Chin-Yang; Wu Wenting; Ketterling Rhett P; Pardanani Animesh; Tefferi Ayalew
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Cancer 2007;109(11):2279-84.
2007: Mesa Ruben A; Verstovsek Srdan; Cervantes Francisco; Barosi Giovanni; Reilly John T; Dupriez Brigitte; Levine Ross; Le Bousse-Kerdiles Marie-Caroline; Wadleigh Martha; Campbell Peter J; Silver Richard T; Vannucchi Alessandro M; Deeg H Joachim; Gisslinger Heinz; Thomas Deborah; Odenike Olatoyosi; Solberg Lawrence A; Gotlib Jason; Hexner Elizabeth; Nimer Stephen D; Kantarjian Hagop; Orazi Attilio; Vardiman James W; Thiele Juergen; Tefferi Ayalew;
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Leukemia research 2007;31(6):737-40.
2007: Tefferi Ayalew; Pardanani Animesh
Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.
Mayo Clinic proceedings. Mayo Clinic 2007;82(5):599-604.
2007: Tefferi Ayalew
Primary myelofibrosis and its paraneoplastic stromal effects.
Haematologica 2007;92(5):577-9.
2007: Patnaik Mrinal M; Rindos Michelle; Kouides Peter A; Tefferi Ayalew; Pardanani Animesh
Systemic mastocytosis: a concise clinical and laboratory review.
Archives of pathology & laboratory medicine 2007;131(5):784-91.
2007: Tefferi Ayalew; Gangat Naseema; Wolanskyj Alexandra
The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia.
Blood 2007;109(9):4105.
2007: Tefferi Ayalew; Huang Jocelin; Schwager Susan; Li Chin-Yang; Wu Wenting; Pardanani Animesh; Mesa Ruben A
Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
Cancer 2007;109(10):2083-8.
2007: Vaklavas C; Tefferi A; Butterfield J; Ketterling R; Verstovsek S; Kantarjian H; Pardanani A
'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.
Leukemia research 2007;31(5):691-4.
2007: Jensen Ashley W; Tefferi Ayalew; Arndt Carola A S
Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2007;29(3):156-9.
2007: Tefferi Ayalew; Gilliland D Gary
Oncogenes in myeloproliferative disorders.
Cell cycle (Georgetown, Tex.) 2007;6(5):550-66.
2007: Tefferi Ayalew; Vardiman James W
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
Current opinion in hematology 2007;14(2):115-22.
2007: Tefferi Ayalew
Ultra high platelet count might be a characteristic feature of chronic myeloid leukemia rather than essential thrombocythemia.
Leukemia research 2007;31(3):416-7.
2007: Tefferi Ayalew
The recent advances in classic BCR-ABL-negative myeloproliferative disorders.
Clinical advances in hematology & oncology : H&O 2007;5(2):113-5.
2007: Tefferi Ayalew
JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
The New England journal of medicine 2007;356(5):444-5.
2007: Gangat N; Wolanskyj A P; McClure R F; Li C-Y; Schwager S; Wu W; Tefferi A
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(2):270-6.
2007: Tefferi Ayalew
Suppressors of cytokine signaling and regulation of clonal erythropoiesis.
Leukemia & lymphoma 2007;48(1):7-8.
2007: Steensma David P; Tefferi Ayalew
Risk-based management of myelodysplastic syndrome.
Oncology (Williston Park, N.Y.) 2007;21(1):43-54; discussion 57-8, 62.
2007: Adjei Alex A; Rajkumar S Vincent; Tefferi Ayalew
Cancer symposium for the practitioner: introduction to solid tumors.
Mayo Clinic proceedings. Mayo Clinic 2007;82(1):107-9.
2007: Mesa Ruben A; Niblack Joyce; Wadleigh Martha; Verstovsek Srdan; Camoriano John; Barnes Sunni; Tan Angelina D; Atherton Pamela J; Sloan Jeff A; Tefferi Ayalew
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
Cancer 2007;109(1):68-76.
2007: Pan Jingxuan; Quintás-Cardama Alfonso; Kantarjian Hagop M; Akin Cem; Manshouri Taghi; Lamb Peter; Cortes Jorge E; Tefferi Ayalew; Giles Francis J; Verstovsek Srdan
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2007: Silver R T; Bennett J M; Goldman J M; Spivak J L; Tefferi A
The third International Congress on Myeloproliferative and Myelodysplastic Syndromes.
Leukemia research 2007;31(1):11-7.
2007: Segovis Colin M; Mueller Paul S; Rethlefsen Melissa L; LaRusso Nicholas F; Litin Scott C; Tefferi Ayalew; Habermann Thomas M
If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center.
BMC medical education 2007;7():22.
2006: Tefferi Ayalew
Genomics basics: DNA structure, gene expression, cloning, genetic mapping, and molecular tests.
Seminars in cardiothoracic and vascular anesthesia 2006;10(4):282-90.
2006: Steensma David P; Caudill Jonathan S C; Pardanani Animesh; McClure Rebecca F; Lasho Terra L; Tefferi Ayalew
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Haematologica 2006;91(12 Suppl):ECR57.
2006: Lasho Terra L; Pardanani Animesh; McClure Rebecca F; Mesa Ruben A; Levine Ross L; Gilliland D Gary; Tefferi Ayalew
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
British journal of haematology 2006;135(5):683-7.
2006: Verstovsek Srdan; Quintás-Cardama Alfonso; Kantarjian Hagop; Tefferi Ayalew
Experimental therapy in myelofibrosis with myeloid metaplasia.
Expert opinion on investigational drugs 2006;15(12):1555-63.
2006: Verstovsek Srdan; Giles Francis J; Quintás-Cardama Alfonso; Manshouri Taghi; Huynh Ly; Manley Paul; Cortes Jorge; Tefferi Ayalew; Kantarjian Hagop
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Pardanani Animesh D; Levine Ross L; Lasho Terra; Pikman Yana; Mesa Ruben A; Wadleigh Martha; Steensma David P; Elliott Michelle A; Wolanskyj Alexandra P; Hogan William J; McClure Rebecca F; Litzow Mark R; Gilliland D Gary; Tefferi Ayalew
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Blood 2006;108(10):3472-6.
2006: Verstovsek Srdan; Akin Cem; Manshouri Taghi; Quintás-Cardama Alfonso; Huynh Ly; Manley Paul; Tefferi Ayalew; Cortes Jorge; Giles Francis J; Kantarjian Hagop
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Mesa Ruben A; Powell Heather; Lasho Terra; Dewald Gordon; McClure Rebecca; Tefferi Ayalew
JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Leukemia research 2006;30(11):1457-60.
2006: Landstrom Andrew P; Ketterling Rhett P; Knudson Ryan A; Tefferi Ayalew
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.
Leukemia & lymphoma 2006;47(10):2055-61.
2006: Tefferi Ayalew; Gangat Naseema; Wolanskyj Alexandra P
Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?
Blood 2006;108(7):2493-4.
2006: Mesa R A; Tefferi A; Lasho T S; Loegering D; McClure R F; Powell H L; Dai N T; Steensma D P; Kaufmann S H
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(10):1800-8.
2006: Gangat Naseema; Wolanskyj Alexandra P; Tefferi Ayalew
Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications.
European journal of haematology 2006;77(4):327-33.
2006: Tefferi Ayalew
Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?
Leukemia & lymphoma 2006;47(9):1724-5.
2006: Tefferi Ayalew; Barosi Giovanni; Mesa Ruben A; Cervantes Francisco; Deeg H Joachim; Reilly John T; Verstovsek Srdan; Dupriez Brigitte; Silver Richard T; Odenike Olatoyosi; Cortes Jorge; Wadleigh Martha; Solberg Lawrence A; Camoriano John K; Gisslinger Heinz; Noel Pierre; Thiele Juergen; Vardiman James W; Hoffman Ronald; Cross Nicholas C P; Gilliland D Gary; Kantarjian Hagop;
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood 2006;108(5):1497-503.
2006: Kamineni Padma; Baptiste Ayanna; Hassan Mukhtar; Dawkins Fitzroy W; Zaidi Syed; Tefferi Ayalew; Lindsey Mercedes; Taddesse-Heath Lekidelu
Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C.
Journal of the National Medical Association 2006;98(8):1356-60.
2006: Moreno-Aspitia Alvaro; Colon-Otero Gerardo; Hoering Antje; Tefferi Ayalew; Niedringhaus Robert D; Vukov Allen; Li Chin-Yang; Menke David M; Geyer Susan M; Alberts Steven R;
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
Cancer 2006;107(4):767-72.
2006: Tefferi Ayalew; Cortes Jorge; Verstovsek Srdan; Mesa Ruben A; Thomas Deborah; Lasho Terra L; Hogan William J; Litzow Mark R; Allred Jacob B; Jones Dan; Byrne Catriona; Zeldis Jerome B; Ketterling Rhett P; McClure Rebecca F; Giles Francis; Kantarjian Hagop M
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood 2006;108(4):1158-64.
2006: Pardanani A; Ketterling R P; Li C-Y; Patnaik M M; Wolanskyj A P; Elliott M A; Camoriano J K; Butterfield J H; Dewald G W; Tefferi A
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Leukemia research 2006;30(8):965-70.
2006: Mesa Ruben A; Nagorney David S; Schwager Susan; Allred Jacob; Tefferi Ayalew
Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.
Cancer 2006;107(2):361-70.
2006: Pardanani Animesh; Lasho Terra; McClure Rebecca; Lacy Martha; Tefferi Ayalew
Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders.
Blood 2006;107(11):4572-3.
2006: Caudill Jonathan S C; Sternberg Alexander J; Li Chin-Yang; Tefferi Ayalew; Lasho Terra L; Steensma David P
C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders.
British journal of haematology 2006;133(6):638-41.
2006: Tefferi Ayalew; Patnaik Mrinal M; Pardanani Animesh
Eosinophilia: secondary, clonal and idiopathic.
British journal of haematology 2006;133(5):468-92.
2006: Buadi F K; Micallef I N; Ansell S M; Porrata L F; Dispenzieri A; Elliot M A; Gastineau D A; Gertz M A; Lacy M Q; Litzow M R; Tefferi A; Inwards D J
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.
Bone marrow transplantation 2006;37(11):1017-22.
2006: Gangat Naseema; Wolanskyj Alexandra P; Schwager Susan M; Mesa Ruben A; Tefferi Ayalew
Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.
Cancer 2006;106(11):2406-11.
2006: Elliott M A; Tefferi A; Hogan W J; Letendre L; Gastineau D A; Ansell S M; Dispenzieri A; Gertz M A; Hayman S R; Inwards D J; Lacy M Q; Micallef I N; Porrata L F; Litzow M R
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
Bone marrow transplantation 2006;37(11):1003-8.
2006: Steensma D P; McClure R F; Karp J E; Tefferi A; Lasho T L; Powell H L; DeWald G W; Kaufmann S H
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):971-8.
2006: Tefferi Ayalew; Pardanani Animesh
Mutation screening for JAK2V617F: when to order the test and how to interpret the results.
Leukemia research 2006;30(6):739-44.
2006: Tefferi Ayalew; Dingli David; Li Chin-Yang; Mesa Ruben A
Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates.
Leukemia research 2006;30(6):677-80.
2006: Pardanani Animesh; Tefferi Ayalew
A role for tryptase in myeloid disorders?
Leukemia & lymphoma 2006;47(5):789-90.
2006: Dingli David; Schwager Susan M; Mesa Ruben A; Li Chin-Yang; Dewald Gordon W; Tefferi Ayalew
Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Cancer 2006;106(9):1985-9.
2006: Tefferi Ayalew; Elliott Michelle A; Pardanani Animesh
Atypical myeloproliferative disorders: diagnosis and management.
Mayo Clinic proceedings. Mayo Clinic 2006;81(4):553-63.
2006: Tefferi Ayalew; Letendre Louis
Drug therapy for myelodysplastic syndrome: building evidence for action.
Cancer 2006;106(8):1650-2.
2006: Tefferi Ayalew; Strand Jacob J; Lasho Terra L; Elliott Michelle A; Li Chin-Yang; Mesa Ruben A; Dewald Gordon W
Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Cancer 2006;106(8):1739-43.
2006: Mesa Ruben A; Powell Heather; Lasho Terra; DeWald Goron W; McClure Rebecca; Tefferi Ayalew
A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
Haematologica 2006;91(3):415-6.
2006: Tefferi Ayalew
Essential thrombocythemia: scientific advances and current practice.
Current opinion in hematology 2006;13(2):93-8.
2006: Tefferi Ayalew
New insights into the pathogenesis and drug treatment of myelofibrosis.
Current opinion in hematology 2006;13(2):87-92.
2006: Landstrom Andrew P; Tefferi Ayalew
Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.
Leukemia & lymphoma 2006;47(3):397-402.
2006: Tefferi Ayalew
Survivorship and prognosis in myelofibrosis with myeloid metaplasia.
Leukemia & lymphoma 2006;47(3):379-80.
2006: Steensma David P; Tefferi Ayalew
Blood vessels everywhere, but so few cells to fill them.
Leukemia & lymphoma 2006;47(3):377-8.
2006: Tefferi Ayalew
Iron chelation therapy for myelodysplastic syndrome: if and when.
Mayo Clinic proceedings. Mayo Clinic 2006;81(2):197-8.
2006: Wolanskyj Alexandra P; Schwager Susan M; McClure Rebecca F; Larson Dirk R; Tefferi Ayalew
Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.
Mayo Clinic proceedings. Mayo Clinic 2006;81(2):159-66.
2006: Dingli David; Schwager Susan M; Mesa Ruben A; Li Chin Yang; Tefferi Ayalew
Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Cancer 2006;106(3):623-30.
2006: Tefferi Ayalew; Lasho Terra L; Schwager Susan M; Strand Jacob S; Elliott Michelle; Mesa Ruben; Li Chin-Yang; Wadleigh Martha; Lee Stephanie J; Gilliland D Gary
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
Cancer 2006;106(3):631-5.
2006: Behl D; Porrata L F; Markovic S N; Letendre L; Pruthi R K; Hook C C; Tefferi A; Elliot M A; Kaufmann S H; Mesa R A; Litzow M R
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(1):29-34.
2006: Tefferi Ayalew
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2006;():240-5.
2006: Litzow M R; Dietz A B; Bulur P A; Butler G W; Gastineau D A; Hoering A; Fink S R; Letendre L; Padley D J; Paternoster S F; Tefferi A; Vuk-Pavlovic S
Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.
Cytotherapy 2006;8(3):290-8.
2006: Mesa Ruben A; Barosi Giovanni; Cervantes Francisco; Reilly John T; Tefferi Ayalew
Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Best practice & research. Clinical haematology 2006;19(3):495-517.
2006: Tefferi Ayalew
The diagnosis of polycythemia vera: new tests and old dictums.
Best practice & research. Clinical haematology 2006;19(3):455-69.
2006: Tefferi Ayalew; Gilliland Gary
Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
Best practice & research. Clinical haematology 2006;19(3):365-85.
2005: Tefferi Ayalew
Pathogenesis of myelofibrosis with myeloid metaplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8520-30.
2005: Tefferi Ayalew; Lasho Terra L; Schwager Susan M; Steensma David P; Mesa Ruben A; Li Chin-Yang; Wadleigh Martha; Gary Gilliland D
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
British journal of haematology 2005;131(3):320-8.
2005: Tefferi Ayalew; Spivak Jerry L
Polycythemia vera: scientific advances and current practice.
Seminars in hematology 2005;42(4):206-20.
2005: Wolanskyj Alexandra P; Lasho Terra L; Schwager Susan M; McClure Rebecca F; Wadleigh Martha; Lee Stephanie J; Gilliland D Gary; Tefferi Ayalew
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
British journal of haematology 2005;131(2):208-13.
2005: Tefferi Ayalew; Sirhan Shireen; Lasho Terra L; Schwager Susan M; Li Chin-Yang; Dingli David; Wolanskyj Alexandra P; Steensma David P; Mesa Ruben; Gilliland D G
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
British journal of haematology 2005;131(2):166-71.
2005: Tefferi Ayalew; Dingli David; Li Chin-Yang; Dewald Gordon W
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
Cancer 2005;104(8):1656-60.
2005: Tefferi Ayalew; Lasho Terra L; Gilliland Gary
JAK2 mutations in myeloproliferative disorders.
The New England journal of medicine 2005;353(13):1416-7; author reply 1416-7.
2005: Tefferi Ayalew; Barbui Tiziano
bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(9):1220-32.
2005: Sharma Sunita; Nadrous Hassan F; Peters Steve G; Tefferi Ayalew; Litzow Mark R; Aubry Marie-Christine; Afessa Bekele
Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings.
Chest 2005;128(3):1385-92.
2005: Lasho Terra L; Mesa Ruben; Gilliland D Gary; Tefferi Ayalew
Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
British journal of haematology 2005;130(5):797-9.
2005: Yoong Yinlee; Porrata Luis F; Inwards David J; Ansell Stephen M; Micallef Ivana N M; Litzow Mark R; Gertz Morie A; Lacy Martha Q; Dispenzieri Angela; Gastineau Dennis A; Tefferi Ayalew; Elliott Michelle; Snow Denis S; Hogan Willian J; Markovic Svetomir N
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma.
Leukemia & lymphoma 2005;46(9):1287-94.
2005: Odenike Olatoyosi; Tefferi Ayalew
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Seminars in oncology 2005;32(4):422-31.
2005: Mesa Ruben A; Tefferi Ayalew
Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia.
Seminars in oncology 2005;32(4):403-13.
2005: Tefferi Ayalew; Rajkumar S Vincent; Adjei Alex A
Introduction to a cancer symposium for the practitioner.
Mayo Clinic proceedings. Mayo Clinic 2005;80(8):1085-6.
2005: Tefferi Ayalew; Gilliland D Gary
JAK2 in myeloproliferative disorders is not just another kinase.
Cell cycle (Georgetown, Tex.) 2005;4(8):1053-6.
2005: Steensma David P; Dewald Gordon W; Lasho Terra L; Powell Heather L; McClure Rebecca F; Levine Ross L; Gilliland D Gary; Tefferi Ayalew
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Blood 2005;106(4):1207-9.
2005: Dingli David; Grand Francis H; Mahaffey Victor; Spurbeck Jack; Ross Fiona M; Watmore Ann E; Reilly John T; Cross Nicholas C P; Dewald Gordon W; Tefferi Ayalew
Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.
British journal of haematology 2005;130(2):229-32.
2005: Wilson Floranne; Tefferi Ayalew
Acute lymphocytic leukemia with eosinophilia: two case reports and a literature review.
Leukemia & lymphoma 2005;46(7):1045-50.
2005: Tefferi Ayalew; Gilliland D Gary
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Mayo Clinic proceedings. Mayo Clinic 2005;80(7):947-58.
2005: Tefferi Ayalew; Hanson Curtis A; Inwards David J
How to interpret and pursue an abnormal complete blood cell count in adults.
Mayo Clinic proceedings. Mayo Clinic 2005;80(7):923-36.
2005: Tefferi Ayalew
Experimental myelofibrosis in mice and the implications to human disease.
Leukemia research 2005;29(7):723-6.
2005: Sirhan Shireen; Fairbanks Virgil F; Tefferi Ayalew
Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility.
Cancer 2005;104(1):213-5.
2005: Dingli David; Tefferi Ayalew
A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Leukemia & lymphoma 2005;46(5):641-50.
2005: Tefferi Ayalew
The rise and fall of red cell mass measurement in polycythemia vera.
Current hematology reports 2005;4(3):213-7.
2005: Tefferi Ayalew
Hydroxyurea vindicated: lack of drug leukemogenicity in polycythemia vera.
Current hematology reports 2005;4(3):211-2.
2005: Jones Letetia C; Tefferi Ayalew; Vuong Peter T; Desmond Julian C; Hofmann Wolf-K; Koeffler H Phillip
Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays.
Stem cells (Dayton, Ohio) 2005;23(5):631-7.
2005: Kumagai Takashi; Tefferi Ayalew; Jones Letetia; Koeffler H Phillip
Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia.
Leukemia research 2005;29(5):511-5.
2005: Levine Ross L; Wadleigh Martha; Cools Jan; Ebert Benjamin L; Wernig Gerlinde; Huntly Brian J P; Boggon Titus J; Wlodarska Iwona; Clark Jennifer J; Moore Sandra; Adelsperger Jennifer; Koo Sumin; Lee Jeffrey C; Gabriel Stacey; Mercher Thomas; D'Andrea Alan; Fröhling Stefan; Döhner Konstanze; Marynen Peter; Vandenberghe Peter; Mesa Ruben A; Tefferi Ayalew; Griffin James D; Eck Michael J; Sellers William R; Meyerson Matthew; Golub Todd R; Lee Stephanie J; Gilliland D Gary
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Cancer cell 2005;7(4):387-97.
2005: Tefferi Ayalew; Dewald Gordon W; Litzow Mark L; Cortes Jorge; Mauro Michael J; Talpaz Moshe; Kantarjian Hagop M
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(3):390-402.
2005: Sirhan Shireen; Lasho Terra L; Elliott Michelle A; Tefferi Ayalew
Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates.
Haematologica 2005;90(3):406-8.
2005: Porrata Luis F; Gertz Morie A; Litzow Mark R; Lacy Martha Q; Dispenzieri Angela; Inwards David J; Ansell Stephen M; Micallef Ivanna N M; Gastineau Dennis A; Elliott Michele; Hogan William J; Hayman Suzanne R; Tefferi Ayalew; Markovic Svetomir N
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1210-8.
2005: Nowakowski Grzegorz S; Morice William G; Phyliky Robert L; Li Chin-Yang; Tefferi Ayalew
Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia.
British journal of haematology 2005;128(4):490-2.
2005: Elliott M A; Tefferi A
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
British journal of haematology 2005;128(3):275-90.
2005: Yoong Yinlee; VanDeWalker Todd J; Carlson Richard O; Dewald Gordon W; Tefferi Ayalew
Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia.
European journal of haematology 2005;74(2):124-7.
2005: Faoro Leonardo N; Tefferi Ayalew; Mesa Ruben A
Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
European journal of haematology 2005;74(2):117-20.
2005: Butterfield Joseph H; Tefferi Ayalew; Kozuh Gerald F
Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.
Leukemia research 2005;29(2):131-4.
2005: Elliott M A; Hanson C A; Dewald G W; Smoley S A; Lasho T L; Tefferi A
WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(2):313-7.
2005: Mesa Ruben A; Li Chin-Yang; Ketterling Rhett P; Schroeder Georgene S; Knudson Ryan A; Tefferi Ayalew
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
Blood 2005;105(3):973-7.
2005: Tefferi Ayalew
The indolent natural history of essential thrombocythemia: a challenge to new drug development.
Mayo Clinic proceedings. Mayo Clinic 2005;80(1):97-8.
2005: Tefferi Ayalew
Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(1):75-83.
2005: Steensma David P; Gibbons Richard J; Mesa Ruben A; Tefferi Ayalew; Higgs Douglas R
Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
European journal of haematology 2005;74(1):47-53.
2005: Ho Ching-Liang; Arora Brijesh; Hoyer James D; Wellik Linda E; Mesa Ruben A; Tefferi Ayalew
Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.
European journal of haematology 2005;74(1):35-9.
2005: Arora Brijesh; Sirhan Shireen; Hoyer James D; Mesa Ruben A; Tefferi Ayalew
Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.
British journal of haematology 2005;128(1):42-8.
2005: Dispenzieri A; Wiseman G A; Lacy M Q; Litzow M R; Anderson P M; Gastineau D A; Tefferi A; Inwards D J; Micallef I N M; Ansell S M; Porrata L; Elliott M A; Lust J A; Greipp P R; Rajkumar S V; Fonseca R; Witzig T E; Erlichman C; Sloan J A; Gertz M A
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(1):118-25.
2005: Tefferi A
Modern diagnosis and treatment of primary eosinophilia.
Acta haematologica 2005;114(1):52-60.
2004: Arora Brijesh; Mesa Ruben; Tefferi Ayalew
Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Leukemia & lymphoma 2004;45(12):2373-86.
2004: Arora Brijesh; Ho Ching-Liang; Hoyer James D; Mesa Ruben A; Tefferi Ayalew
Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
Haematologica 2004;89(12):1454-8.
2004: Gertz M A; Lacy M Q; Dispenzieri A; Ansell S M; Elliott M A; Gastineau D A; Inwards D J; Micallef I N M; Porrata L F; Tefferi A; Litzow M R
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Bone marrow transplantation 2004;34(12):1025-31.
2004: Jurgens Donald J; Moreno-Aspitia Alvaro; Tefferi Ayalew
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Haematologica 2004;89(11):1394-5.
2004: Pardanani Animesh; Brockman Stephanie R; Paternoster Sarah F; Flynn Heather C; Ketterling Rhett P; Lasho Terra L; Ho Ching-Liang; Li Chin-Yang; Dewald Gordon W; Tefferi Ayalew
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
Blood 2004;104(10):3038-45.
2004: Dispenzieri Angela; Moreno-Aspitia Alvaro; Suarez Guillermo A; Lacy Martha Q; Colon-Otero Gerardo; Tefferi Ayalew; Litzow Mark R; Roy Vivek; Hogan William J; Kyle Robert A; Gertz Morie A
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature.
Blood 2004;104(10):3400-7.
2004: Koch Cody A; Lasho Terra L; Tefferi Ayalew
Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay.
British journal of haematology 2004;127(1):34-9.
2004: Jones Letetia C; Tefferi Ayalew; Idos Gregory E; Kumagai Takashi; Hofmann Wolf-K; Koeffler H Phillip
RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia.
Oncogene 2004;23(47):7846-53.
2004: Pardanani Animesh; Tefferi Ayalew
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
Blood 2004;104(7):1931-9.
2004: Poulin Veronique; Chopra Ashish; Tefferi Ayalew
80-year-old man with anemia and blistering skin lesions.
Mayo Clinic proceedings. Mayo Clinic 2004;79(9):1181-4.
2004: Greipp Patricia T; Dewald Gordon W; Tefferi Ayalew
Prevalence, breakpoint distribution, and clinical correlates of t(5;12).
Cancer genetics and cytogenetics 2004;153(2):170-2.
2004: Elliott Michelle A; Tefferi Ayalew
Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Current hematology reports 2004;3(5):344-51.
2004: Dispenzieri Angela; Gertz Morie A; Kyle Robert A; Lacy Martha Q; Burritt Mary F; Therneau Terry M; McConnell Joseph P; Litzow Mark R; Gastineau Dennis A; Tefferi Ayalew; Inwards David J; Micallef Ivana N; Ansell Stephen M; Porrata Luis F; Elliott Michelle A; Hogan William J; Rajkumar S Vincent; Fonseca Rafael; Greipp Philip R; Witzig Thomas E; Lust John A; Zeldenrust Steven R; Snow Denise S; Hayman Susan R; McGregor Christopher G A; Jaffe Allan S
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
Blood 2004;104(6):1881-7.
2004: Elliott Michelle A; Wolf Robert C; Hook Christopher C; Pruthi Rajiv K; Heit John A; Letendre Louis L; Tefferi Ayalew; Kaufmann Scott H; Mesa Ruben A; Litzow Mark R
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Leukemia & lymphoma 2004;45(8):1545-9.
2004: You Y Nancy; Tefferi Ayalew; Nagorney David M
Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus.
Annals of surgery 2004;240(2):286-92.
2004: Dingli David; Tefferi Ayalew
Anagrelide: an update on its mechanisms of action and therapeutic potential.
Expert review of anticancer therapy 2004;4(4):533-41.
2004: Pardanani A; Kimlinger T; Reeder T; Li C-Y; Tefferi A
Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients.
Leukemia research 2004;28(8):777-83.
2004: Dingli David; Mesa Ruben A; Tefferi Ayalew
Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.
Internal medicine (Tokyo, Japan) 2004;43(7):540-7.
2004: Tefferi Ayalew; Lasho Terra L; Brockman Stephanie R; Elliott Michelle A; Dispenzieri Angela; Pardanani Animesh
FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.
Haematologica 2004;89(7):871-3.
2004: Tefferi Ayalew
Practical algorithms in anemia diagnosis.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):955-6.
2004: Tefferi Ayalew; Deeg H Joachim
Deciding on transplantation for myelofibrosis: setting the record straight.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):953-4.
2004: Mesa Ruben A; Elliott Michelle A; Schroeder Georgene; Tefferi Ayalew
Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):883-9.
2004: Tefferi Ayalew; Pardanani Animesh
Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
International journal of hematology 2004;79(5):441-7.
2004: Tefferi Ayalew; Elliott Michelle A
Schistocytes on the peripheral blood smear.
Mayo Clinic proceedings. Mayo Clinic 2004;79(6):809.
2004: Tefferi Ayalew; Spelsberg Thomas C
Primer on medical genomics. The end of the beginning.
Mayo Clinic proceedings. Mayo Clinic 2004;79(5):659-60.
2004: Hook C Christopher; DiMagno Eugene P; Tefferi Ayalew
Primer on medical genomics. Part XIII: Ethical and regulatory issues.
Mayo Clinic proceedings. Mayo Clinic 2004;79(5):645-50.
2004: Tefferi Ayalew; Pardanani Animesh
Systemic mastocytosis: current concepts and treatment advances.
Current hematology reports 2004;3(3):197-202.
2004: Tefferi Ayalew
A novel pathogenetic mutation in clonal eosinophilia.
Current hematology reports 2004;3(3):195-6.
2004: Pardanani Animesh; Tefferi Ayalew
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Leukemia research 2004;28 Suppl 1():S47-52.
2004: Dispenzieri Angela; Kyle Robert A; Lacy Martha Q; Therneau Terry M; Larson Dirk R; Plevak Matthew F; Rajkumar S Vincent; Fonseca Rafael; Greipp Philip R; Witzig Thomas E; Lust John A; Zeldenrust Steven R; Snow Denise S; Hayman Susan R; Litzow Mark R; Gastineau Dennis A; Tefferi Ayalew; Inwards David J; Micallef Ivana N; Ansell Stephen M; Porrata Luis F; Elliott Michelle A; Gertz Morie A
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
Blood 2004;103(10):3960-3.
2004: Tefferi Ayalew; Lasho Terra L; Wolanskyj Alexandra P; Mesa Ruben A
Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.
Blood 2004;103(9):3547-8.
2004: Nadrous Hassan F; Krowka Michael J; McClure Rebecca F; Tefferi Ayalew; Lim Kaiser G
Agnogenic myeloid metaplasia with pleural extramedullary leukemic transformation.
Leukemia & lymphoma 2004;45(4):815-8.
2004: Tefferi Ayalew; Nagorney David M
The spleen in myelofibrosis with myeloid metaplasia.
Mayo Clinic proceedings. Mayo Clinic 2004;79(4):503.
2004: Tefferi Ayalew
Treatment of systemic mast cell disease: beyond interferon.
Leukemia research 2004;28(3):223-4.
2004: Tefferi Ayalew; Colgan Joseph P
Breast peau d'orange from large cell lymphoma.
Mayo Clinic proceedings. Mayo Clinic 2004;79(2):187.
2004: Pardanani A; Hoffbrand A V; Butterfield J H; Tefferi A
Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.
Leukemia research 2004;28(2):127-31.
2004: Afshar-Kharghan Vahid; López José A; Gray Leigh A; Padilla Arnoldo; Borthakur Gautam; Roberts Stacy C; Pruthi Rajiv K; Tefferi Ayalew
Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2004;15(1):21-4.
2004: Tefferi Ayalew; Pardanani Animesh
Clinical, genetic, and therapeutic insights into systemic mast cell disease.
Current opinion in hematology 2004;11(1):58-64.
2004: O'Brien Stephen; Tefferi Ayalew; Valent Peter
Chronic myelogenous leukemia and myeloproliferative disease.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():146-62.
2003: Huber M R; Kumar S; Tefferi A
Treatment advances in adult immune thrombocytopenic purpura.
Annals of hematology 2003;82(12):723-37.
2003: Chandra Joya; Hackbarth Jennifer; Le Son; Loegering David; Bone Nancy; Bruzek Laura M; Narayanan Ven L; Adjei Alex A; Kay Neil E; Tefferi Ayalew; Karp Judith E; Sausville Edward A; Kaufmann Scott H
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Blood 2003;102(13):4512-9.
2003: Shanafelt Tait D; Madueme Hans L; Wolf Robert C; Tefferi Ayalew
Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Mayo Clinic proceedings. Mayo Clinic 2003;78(11):1340-6.
2003: Pardanani Animesh; Ketterling Rhett P; Brockman Stephanie R; Flynn Heather C; Paternoster Sarah F; Shearer Brandon M; Reeder Terra L; Li Chin-Yang; Cross Nicholas C P; Cools Jan; Gilliland D Gary; Dewald Gordon W; Tefferi Ayalew
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Blood 2003;102(9):3093-6.
2003: Tefferi Ayalew
Anemia in adults: a contemporary approach to diagnosis.
Mayo Clinic proceedings. Mayo Clinic 2003;78(10):1274-80.
2003: Koch Cody A; Li Chin-Yang; Mesa Ruben A; Tefferi Ayalew
Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.
Mayo Clinic proceedings. Mayo Clinic 2003;78(10):1223-33.
2003: Tefferi Ayalew; Pardanani Animesh; Li Chin-Yang
Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?
Blood 2003;102(8):3073-4; author reply 3074.
2003: Neben Michelle A; Morice William G; Tefferi Ayalew
Clinical features in T-cell vs. natural killer-cell variants of large granular lymphocyte leukemia.
European journal of haematology 2003;71(4):263-5.
2003: Pardanani Animesh; Reeder Terra; Li Chin-Yang; Tefferi Ayalew
Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.
Leukemia research 2003;27(10):883-5.
2003: Kumar S; Chen M G; Gastineau D A; Gertz M A; Inwards D J; Lacy M Q; Tefferi A; Litzow M R
Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(9):1865-70.
2003: Steensma David P; Mesa Ruben A; Reeder Terra L; Tefferi Ayalew; Kaufmann Scott H
Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.
Haematologica 2003;88(9):1072-4.
2003: Steensma David P; Tefferi Ayalew; Li Chin-Yang
Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome.
Leukemia research 2003;27(9):775-82.
2003: Pardanani A; Elliott M; Reeder T; Li C Y; Baxter E J; Cross N C P; Tefferi A
Imatinib for systemic mast-cell disease.
Lancet 2003;362(9383):535-6.
2003: Deb Arjun; Tefferi Ayalew
Images in clinical medicine. Systemic mastocytosis.
The New England journal of medicine 2003;349(7):e7.
2003: Maziarz Richard T; Mesa Ruben A; Tefferi Ayalew
Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?".
Mayo Clinic proceedings. Mayo Clinic 2003;78(8):941-3.
2003: Howe R; Micallef I N M; Inwards D J; Ansell S M; Dewald G W; Dispenzieri A; Gastineau D A; Gertz M A; Geyer S M; Hanson C A; Lacy M Q; Tefferi A; Litzow M R
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
Bone marrow transplantation 2003;32(3):317-24.
2003: Pardanani Animesh; Reeder Terra L; Kimlinger Teresa K; Baek Jin Y; Li Chin-Y; Butterfield Joseph H; Tefferi Ayalew
Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease.
Leukemia research 2003;27(8):739-42.
2003: Ensenauer Regina E; Reinke Shanda S; Ackerman Michael J; Tester David J; Whiteman David A H; Tefferi Ayalew
Primer on medical genomics. Part VIII: Essentials of medical genetics for the practicing physician.
Mayo Clinic proceedings. Mayo Clinic 2003;78(7):846-57.
2003: Pardanani Animesh D; Morice William G; Hoyer James D; Tefferi Ayalew
Chronic basophilic leukemia: a distinct clinico-pathologic entity?
European journal of haematology 2003;71(1):18-22.
2003: Afessa Bekele; Tefferi Ayalew; Dunn William F; Litzow Mark R; Peters Steve G
Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients.
Critical care medicine 2003;31(6):1715-21.
2003: Elliott Michelle A; Tefferi Ayalew
Thrombocythaemia and pregnancy.
Best practice & research. Clinical haematology 2003;16(2):227-42.
2003: Chou Jung M; Li Chin-Yang; Tefferi Ayalew
Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.
Leukemia research 2003;27(6):499-504.
2003: Tefferi Ayalew
A contemporary approach to the diagnosis and management of polycythemia vera.
Current hematology reports 2003;2(3):237-41.
2003: Mesa R A; Tefferi A; Gray L A; Reeder T; Schroeder G; Kaufmann S H
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(5):849-55.
2003: Kumar Shaji; DeLeve Laurie D; Kamath Patrick S; Tefferi Ayalew
Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation.
Mayo Clinic proceedings. Mayo Clinic 2003;78(5):589-98.
2003: Pardanani Animesh; Reeder Terra; Porrata Luis F; Li Chin-Yang; Tazelaar Henry D; Baxter E Joanna; Witzig Thomas E; Cross Nicholas C P; Tefferi Ayalew
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
Blood 2003;101(9):3391-7.
2003: Elliott Michelle A; Nichols William L; Plumhoff Elizabeth A; Ansell Stephen M; Dispenzieri Angela; Gastineau Dennis A; Gertz Morie A; Inwards David J; Lacy Martha Q; Micallef Ivana N M; Tefferi Ayalew; Litzow Mark
Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.
Mayo Clinic proceedings. Mayo Clinic 2003;78(4):421-30.
2003: Mesa Ruben A; Steensma David P; Pardanani Animesh; Li Chin-Yang; Elliott Michelle; Kaufmann Scott H; Wiseman Gregory; Gray Leigh A; Schroeder Georgene; Reeder Terra; Zeldis Jerome B; Tefferi Ayalew
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Blood 2003;101(7):2534-41.
2003: Jiménez Teresa M; Patel Sachin B; Pineda Alvaro A; Tefferi Ayalew; Owen Whyte G
Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility.
Transfusion 2003;43(3):328-34.
2003: Cools Jan; DeAngelo Daniel J; Gotlib Jason; Stover Elizabeth H; Legare Robert D; Cortes Jorges; Kutok Jeffrey; Clark Jennifer; Galinsky Ilene; Griffin James D; Cross Nicholas C P; Tefferi Ayalew; Malone James; Alam Rafeul; Schrier Stanley L; Schmid Janet; Rose Michal; Vandenberghe Peter; Verhoef Gregor; Boogaerts Marc; Wlodarska Iwona; Kantarjian Hagop; Marynen Peter; Coutre Steven E; Stone Richard; Gilliland D Gary
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
The New England journal of medicine 2003;348(13):1201-14.
2003: Morice William G; Kurtin Paul J; Leibson Paul J; Tefferi Ayalew; Hanson Curtis A
Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia.
British journal of haematology 2003;120(6):1026-36.
2003: Ansell Stephen M; Ackerman Michael J; Black John L; Roberts Lewis R; Tefferi Ayalew
Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice.
Mayo Clinic proceedings. Mayo Clinic 2003;78(3):307-17.
2003: Pardanani Animesh; Phyliky Robert L; Li Chin-Yang; Tefferi Ayalew
2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis.
Mayo Clinic proceedings. Mayo Clinic 2003;78(3):301-6.
2003: Steensma David P; Dewald Gordon W; Hodnefield Janice M; Tefferi Ayalew; Hanson Curtis A
Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?
Leukemia research 2003;27(3):235-42.
2003: Steensma David P; Dispenzieri Angela; Moore S Breanndan; Schroeder Georgene; Tefferi Ayalew
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.
Blood 2003;101(6):2156-8.
2003: Reeder Terra L; Bailey Richard J; Dewald Gordon W; Tefferi Ayalew
Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.
Blood 2003;101(5):1981-3.
2003: Pardanani Animesh; Kimlinger Teresa K; Reeder Terra L; Li Chin-Yang; Tefferi Ayalew
Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder.
British journal of haematology 2003;120(4):691-4.
2003: Tefferi Ayalew
Polycythemia vera: a comprehensive review and clinical recommendations.
Mayo Clinic proceedings. Mayo Clinic 2003;78(2):174-94.
2003: Tefferi Ayalew
Thrombopoietin expression and plasma concentrations in chronic myeloproliferative disorders.
Leukemia research 2003;27(2):121-3.
2003: Steensma David P; Tefferi Ayalew
The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.
Leukemia research 2003;27(2):95-120.
2003: Tefferi Ayalew
Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Seminars in hematology 2003;40(1 Suppl 1):18-21.
2003: Tefferi Ayalew
The forgotten myeloproliferative disorder: myeloid metaplasia.
The oncologist 2003;8(3):225-31.
2002: Vanness Erin R; Davis Mark D P; Tefferi Ayalew
Cutaneous findings associated with chronic natural killer cell lymphocytosis.
International journal of dermatology 2002;41(12):852-7.
2002: Litzow Mark R; Repoussis Panagiotis D; Schroeder Georgene; Schembri-Wismayer David; Batts Kenneth P; Anderson Peter M; Arndt Carola A S; Chen Michael G; Gastineau Dennis A; Gertz Morie A; Inwards David J; Lacy Martha Q; Tefferi Ayalew; Noël Pierre; Solberg Lawrence A; Letendre Louis; Hoagland H Clark
Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator.
Leukemia & lymphoma 2002;43(11):2099-107.
2002: Gertz Morie A; Lacy Martha Q; Dispenzieri Angela; Gastineau Dennis A; Chen Michael G; Ansell Stephen M; Inwards David J; Micallef Ivana N M; Tefferi Ayalew; Litzow Mark R
Stem cell transplantation for the management of primary systemic amyloidosis.
The American journal of medicine 2002;113(7):549-55.
2002: Pardanani Animesh; Wieben Eric D; Spelsberg Thomas C; Tefferi Ayalew
Primer on medical genomics. Part IV: Expression proteomics.
Mayo Clinic proceedings. Mayo Clinic 2002;77(11):1185-96.
2002: Pardanani Animesh; Baek Jin-Young; Li Chin-Yang; Butterfield Joseph H; Tefferi Ayalew
Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study.
Mayo Clinic proceedings. Mayo Clinic 2002;77(11):1169-75.
2002: Afessa Bekele; Tefferi Ayalew; Litzow Mark R; Peters Steve G
Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.
American journal of respiratory and critical care medicine 2002;166(10):1364-8.
2002: Gumina Richard J; Foley David A; Tefferi Ayalew; Rooke Thom W; Shields Raymond C
Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosis.
Angiology 2002;53(5):587-91.
2002: Tefferi Ayalew; Bolander Mark E; Ansell Stephen M; Wieben Eric D; Spelsberg Thomas C
Primer on medical genomics. Part III: Microarray experiments and data analysis.
Mayo Clinic proceedings. Mayo Clinic 2002;77(9):927-40.
2002: Afessa Bekele; Tefferi Ayalew; Litzow Mark R; Krowka Michael J; Wylam Mark E; Peters Steve G
Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.
American journal of respiratory and critical care medicine 2002;166(5):641-5.
2002: Steensma David P; Hook C Christopher; Stafford Scott L; Tefferi Ayalew
Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia.
British journal of haematology 2002;118(3):813-6.
2002: Kumar S; Wolf R C; Chen M G; Gastineau D A; Gertz M A; Inwards D J; Lacy M Q; Tefferi A; Litzow M R
Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
Bone marrow transplantation 2002;30(3):161-5.
2002: Tefferi Ayalew; Wieben Eric D; Dewald Gordon W; Whiteman David A H; Bernard Matthew E; Spelsberg Thomas C
Primer on medical genomics part II: Background principles and methods in molecular genetics.
Mayo Clinic proceedings. Mayo Clinic 2002;77(8):785-808.
2002: Hogan William J; Letendre Louis; Litzow Mark R; Tefferi Ayalew; Hoagland H Clark; Pruthi Rajiv K; Kaufmann Scott H
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside.
Mayo Clinic proceedings. Mayo Clinic 2002;77(8):760-2.
2002: Porrata L F; Litzow M R; Tefferi A; Letendre L; Kumar S; Geyer S M; Markovic S N
Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(7):1311-8.
2002: Rao Ravi D; Swanson Jerry W; Dejesus Ramona S; Hunt Christopher H; Tefferi Ayalew
Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia.
Leukemia & lymphoma 2002;43(6):1333-6.
2002: Kumar S; Diehn F E; Gertz M A; Tefferi A
Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses.
Annals of hematology 2002;81(6):312-9.
2002: Mesa Ruben A; Hanson Curtis A; Li Chin-Yang; Yoon Soo-Young; Rajkumar S Vincent; Schroeder Georgene; Tefferi Ayalew
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia.
Blood 2002;99(11):4131-7.
2002: Gleich Gerald J; Leiferman Kristin M; Pardanani Animesh; Tefferi Ayalew; Butterfield Joseph H
Treatment of hypereosinophilic syndrome with imatinib mesilate.
Lancet 2002;359(9317):1577-8.
2002: Tefferi Ayalew; Mesa Ruben A; Gray Leigh A; Steensma David P; Camoriano John K; Elliott Michelle A; Pardanani Animesh; Ansell Stephen M; Call Timothy G; Colon-Otero Gerardo; Schroeder Georgene; Hanson Curtis A; Dewald Gordon W; Kaufmann Scott H
Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.
Blood 2002;99(10):3854-6.
2002: Elliott Michelle A; Mesa Ruben A; Li Chin-Yang; Hook C Christopher; Ansell Stephen M; Levitt Ralph M; Geyer Susan M; Tefferi Ayalew
Thalidomide treatment in myelofibrosis with myeloid metaplasia.
British journal of haematology 2002;117(2):288-96.
2002: Tefferi Ayalew; Fonseca Rafael
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.
Blood 2002;99(7):2627.
2002: Elliot Michelle A; Yoon Soo-Young; Kao Pai; Li Chin-Yang; Tefferi Ayalew
Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia.
European journal of haematology 2002;68(3):175-9.
2002: Elliott Michelle A; Letendre Louis; Hanson Curtis A; Tefferi Ayalew; Dewald Gordon W
The prognostic significance of trisomy 8 in patients with acute myeloid leukemia.
Leukemia & lymphoma 2002;43(3):583-6.
2002: Steensma David P; Mesa Ruben A; Li Chin-Yang; Gray Leigh; Tefferi Ayalew
Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.
Blood 2002;99(6):2252-4.
2002: Elliott Michelle A; Mesa Ruben A; Tefferi Ayalew
Adverse events after imatinib mesylate therapy.
The New England journal of medicine 2002;346(9):712-3.
2002: Baek Jin-Young; Li Chin-Yang; Pardanani Animesh; Butterfield Joseph H; Tefferi Ayalew
Bone marrow angiogenesis in systemic mast cell disease.
Journal of hematotherapy & stem cell research 2002;11(1):139-46.
2002: Rajkumar S Vincent; Mesa Ruben A; Tefferi Ayalew
A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies.
Journal of hematotherapy & stem cell research 2002;11(1):33-47.
2002: Tefferi Ayalew
Current management of polycythemia vera.
Leukemia & lymphoma 2002;43(1):1-7.
2002: Mow Benjamin M F; Chandra Joya; Svingen Phyllis A; Hallgren Christopher G; Weisberg Ellen; Kottke Timothy J; Narayanan Ven L; Litzow Mark R; Griffin James D; Sausville Edward A; Tefferi Ayalew; Kaufmann Scott H
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Blood 2002;99(2):664-71.
2002: Morice William G; Kurtin Paul J; Tefferi Ayalew; Hanson Curtis A
Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B.
Blood 2002;99(1):268-74.
2002: Baek Jin-Young; Tefferi Ayalew; Pardanani Animesh; Li Chin-Yang
Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.
Leukemia research 2002;26(1):83-90.
2002: Steensma David P; Tefferi Ayalew
Cytogenetic and molecular genetic aspects of essential thrombocythemia.
Acta haematologica 2002;108(2):55-65.
2001: Diehn F; Tefferi A
Pruritus in polycythaemia vera: prevalence, laboratory correlates and management.
British journal of haematology 2001;115(3):619-21.
2001: Steensma D P; Harrison C N; Tefferi A
Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review.
Leukemia & lymphoma 2001;42(6):1243-53.
2001: Steensma D P; Tefferi A
Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience.
Leukemia & lymphoma 2001;42(6):1229-34.
2001: Tack D K; Letendre L; Kamath P S; Tefferi A
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
Bone marrow transplantation 2001;28(9):895-7.
2001: Tefferi A; Kumar S; Wolf R C; Lacy M Q; Inwards D J; Gloor J M; Albright R C; Kamath P S; Litzow M R
Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
Bone marrow transplantation 2001;28(10):997-9.
2001: Kumar S; Chen M G; Gastineau D A; Gertz M A; Inwards D J; Lacy M Q; Tefferi A; Litzow M R
Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia.
Bone marrow transplantation 2001;28(10):951-6.
2001: Tefferi A; Meyer R G; Wyatt W A; Dewald G W
Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia.
British journal of haematology 2001;115(2):316-9.
2001: Steensma D P; Hanson C A; Letendre L; Tefferi A
Myelodysplasia with fibrosis: a distinct entity?
Leukemia research 2001;25(10):829-38.
2001: Tefferi A; Murphy S
Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.
Blood reviews 2001;15(3):121-31.
2001: Mesa R A; Tefferi A
Palliative splenectomy in myelofibrosis with myeloid metaplasia.
Leukemia & lymphoma 2001;42(5):901-11.
2001: Dingli D; Utz J P; Krowka M J; Oberg A L; Tefferi A
Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
Chest 2001;120(3):801-8.
2001: Tefferi A; Li C Y; Reeder C B; Geyer S M; Allmer C; Levitt R; Michalak J C; Addo F; Krook J E; Witzig T E; Schaefer P L; Mailliard J A
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(8):1171-5.
2001: Anderson J E; Tefferi A; Craig F; Holmberg L; Chauncey T; Appelbaum F R; Guardiola P; Callander N; Freytes C; Gazitt Y; Razvillas B; Deeg H J
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.
Blood 2001;98(3):586-93.
2001: Porrata L F; Gertz M A; Inwards D J; Litzow M R; Lacy M Q; Tefferi A; Gastineau D A; Dispenzieri A; Ansell S M; Micallef I N; Geyer S M; Markovic S N
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Blood 2001;98(3):579-85.
2001: Kumar S; Tefferi A
Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature.
Annals of hematology 2001;80(7):430-5.
2001: Mesa R A; Tefferi A; Elliott M A; Hoagland H C; Call T G; Schroeder G S; Yoon S Y; Li C Y; Gray L A; Margolin S; Hook C C
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.
British journal of haematology 2001;114(1):111-3.
2001: Go R S; Li C Y; Tefferi A; Phyliky R L
Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes.
Blood 2001;98(2):483-5.
2001: Kumar S; Chen M G; Gastineau D A; Gertz M A; Inwards D J; Lacy M Q; Tefferi A; Harmsen W S; Litzow M R
Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Bone marrow transplantation 2001;27(11):1133-40.
2001: Capizzi S A; Kumar S; Huneke N E; Gertz M A; Inwards D J; Litzow M R; Lacy M Q; Gastineau D A; Prakash U B; Tefferi A
Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation.
Bone marrow transplantation 2001;27(12):1299-303.
2001: Tefferi A; Mesa R A; Schroeder G; Hanson C A; Li C Y; Dewald G W
Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.
British journal of haematology 2001;113(3):763-71.
2001: Mesa R A; Li C Y; Schroeder G; Tefferi A
Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.
Blood 2001;97(11):3665-7.
2001: Greenlund L J; Letendre L; Tefferi A
Acute leukemia during pregnancy: a single institutional experience with 17 cases.
Leukemia & lymphoma 2001;41(5-6):571-7.
2001: Morice W G; Leibson P J; Tefferi A
Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis.
Leukemia & lymphoma 2001;41(3-4):277-84.
2001: Wright C A; Tefferi A
A single institutional experience with 43 pregnancies in essential thrombocythemia.
European journal of haematology 2001;66(3):152-9.
2001: Barron B A; Hoyer J D; Tefferi A
A bone marrow report of absent stainable iron is not diagnostic of iron deficiency.
Annals of hematology 2001;80(3):166-9.
2001: Tefferi A; Elliot M A; Yoon S Y; Li C Y; Mesa R A; Call T G; Dispenzieri A
Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.
Blood 2001;97(6):1896.
2001: Tefferi A
The pathogenesis of chronic myeloproliferative diseases.
International journal of hematology 2001;73(2):170-6.
2001: Tefferi A; Elliott M A; Steensma D P; Hook C C; Dispenzieria A; Hanson C A; Schroeder G; Letendre L
Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
Leukemia research 2001;25(2):183-5.
2001: Storen E C; Tefferi A
Long-term use of anagrelide in young patients with essential thrombocythemia.
Blood 2001;97(4):863-6.
2001: Elliott M A; Dewald G W; Tefferi A; Hanson C A
Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(1):35-40.
2001: Tefferi A
Chronic myeloid disorders: Classification and treatment overview.
Seminars in hematology 2001;38(1 Suppl 2):1-4.
2001: Tefferi A; Jiménez T; Gray L A; Mesa R A; Chen M G
Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia.
European journal of haematology 2001;66(1):37-42.
2001: Tefferi A; Fonseca R; Pereira D L; Hoagland H C
A long-term retrospective study of young women with essential thrombocythemia.
Mayo Clinic proceedings. Mayo Clinic 2001;76(1):22-8.
2000: Gertz M A; Lacy M Q; Gastineau D A; Inwards D J; Chen M G; Tefferi A; Kyle R A; Litzow M R
Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
Bone marrow transplantation 2000;26(9):963-9.
2000: Fairbanks V F; Tefferi A
Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to 'apparent polycythemia'.
European journal of haematology 2000;65(5):285-96.
2000: Go R S; Tefferi A; Li C Y; Lust J A; Phyliky R L
Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia.
Blood 2000;96(10):3644-6.
2000: Mesa R A; Hanson C A; Rajkumar S V; Schroeder G; Tefferi A
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia.
Blood 2000;96(10):3374-80.
2000: Yoon S Y; Li C Y; Lloyd R V; Tefferi A
Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders.
International journal of hematology 2000;72(3):337-42.
2000: Mesa R A; Elliott M A; Tefferi A
Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
Blood reviews 2000;14(3):121-9.
2000: Tefferi A; Solberg L A; Silverstein M N
A clinical update in polycythemia vera and essential thrombocythemia.
The American journal of medicine 2000;109(2):141-9.
2000: Steensma D P; Tefferi A; Weiler C R
Autoimmune hemolytic anemia in a patient with autosomal dominant chronic mucocutaneous candidiasis.
Mayo Clinic proceedings. Mayo Clinic 2000;75(8):853-5.
2000: Tefferi A; Elliott M A; Kao P C; Yoon S; El-Hemaidi I; Pearson T C
Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera.
Blood 2000;96(4):1582-4.
2000: Gertz M A; Lacy M Q; Inwards D J; Gastineau D A; Tefferi A; Chen M G; Witzig T E; Greipp P R; Litzow M R
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
Bone marrow transplantation 2000;26(1):45-50.
2000: Tefferi A; Yoon S Y; Li C Y
Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis.
Blood 2000;96(2):771-2.
2000: Tefferi A
Myelofibrosis with myeloid metaplasia.
The New England journal of medicine 2000;342(17):1255-65.
2000: Tefferi A; Mesa R A; Nagorney D M; Schroeder G; Silverstein M N
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
Blood 2000;95(7):2226-33.
2000: Dietz A B; Bulur P A; Erickson M R; Wettstein P J; Litzow M R; Wyatt W A; Dewald G W; Tefferi A; Pankratz V S; Vuk-Pavlovic S
Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
Journal of hematotherapy & stem cell research 2000;9(1):95-101.
2000: Menke D M; Griesser H; Moder K G; Tefferi A; Luthra H S; Cohen M D; Colon-Otero G; Lloyd R V
Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate.
American journal of clinical pathology 2000;113(2):212-8.
2000: Svingen P A; Tefferi A; Kottke T J; Kaur G; Narayanan V L; Sausville E A; Kaufmann S H
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):237-49.
2000: Yoon S Y; Tefferi A; Li C Y
Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow.
Acta haematologica 2000;104(4):151-7.
1999: Tefferi A; Levitt R; Li C Y; Schroeder G; Tschetter L K; Michalak J C; Krook J E; Witzig T E
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia.
American journal of clinical oncology 1999;22(5):509-16.
1999: Elliott M A; Tefferi A
Splenic irradiation in myelofibrosis with myeloid metaplasia: a review.
Blood reviews 1999;13(3):163-70.
1999: Rabbani G R; Phyliky R L; Tefferi A
A long-term study of patients with chronic natural killer cell lymphocytosis.
British journal of haematology 1999;106(4):960-6.
1999: Letendre L; Noel P; White W L; Tefferi A; Litzow M R; Li C Y; Schroeder G
Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C.
Leukemia research 1999;23(9):811-5.
1999: Yoon S Y; Li C Y; Mesa R A; Tefferi A
Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.
British journal of haematology 1999;106(3):682-8.
1999: Mesa R A; Silverstein M N; Jacobsen S J; Wollan P C; Tefferi A
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.
American journal of hematology 1999;61(1):10-5.
1999: Hogan W J; Tefferi A; Borell T J; Jenkins R; Li C Y; Witzig T E
Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 1999;110(2):77-81.
1999: Tefferi A; Inwards D J; Hoyer J D
Spontaneous remission of anemia associated with a myelodysplastic syndrome with disease evolution into a myeloproliferative state.
Acta haematologica 1999;101(1):50-2.
1999: Gertz M A; Lacy M Q; Inwards D J; Chen M G; Pineda A A; Gastineau D A; Greipp P R; Lust J A; Tefferi A; Witzig T E; Kyle R A; Litzow M R
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Bone marrow transplantation 1999;23(3):221-6.
1999: Tefferi A
Diagnosing polycythemia vera: a paradigm shift.
Mayo Clinic proceedings. Mayo Clinic 1999;74(2):159-62.
1999: Silverstein M N; Tefferi A
Treatment of essential thrombocythemia with anagrelide.
Seminars in hematology 1999;36(1 Suppl 2):23-5.
1999: Tefferi A
Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Seminars in hematology 1999;36(1 Suppl 2):3-8.
1999: Tefferi A
Introduction: overview of chronic myeloproliferative disorders.
Seminars in hematology 1999;36(1 Suppl 2):1-2.
1998: Tefferi A; Silverstein M N
Treatment of polycythaemia vera and essential thrombocythaemia.
Baillière's clinical haematology 1998;11(4):769-85.
1998: Tefferi A
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Mayo Clinic proceedings. Mayo Clinic 1998;73(12):1177-84.
1998: Elliott M A; Chen M G; Silverstein M N; Tefferi A
Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.
British journal of haematology 1998;103(2):505-11.
1998: Fonseca R; Rajkumar S V; White W L; Tefferi A; Hoagland H C
Anemia after orchiectomy.
American journal of hematology 1998;59(3):230-3.
1998: Fonseca R; Yamakawa M; Nakamura S; van Heerde P; Miettinen M; Shek T W; Myhre Jensen O; Rousselet M C; Tefferi A
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review.
American journal of hematology 1998;59(2):161-7.
1998: Letendre L; Noel P; Litzow M R; Hoagland H C; Tefferi A
Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C.
American journal of clinical oncology 1998;21(2):142-4.
1998: Palmas A; Tefferi A; Myers J L; Scott J P; Swensen S J; Chen M G; Gastineau D A; Gertz M A; Inwards D J; Lacy M Q; Litzow M R
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation.
British journal of haematology 1998;100(4):680-7.
1997: Tefferi A; Nichols W L
Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment.
The American journal of medicine 1997;103(6):536-40.
1997: Tefferi A; Silverstein M N; Li C Y
2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia.
British journal of haematology 1997;99(2):352-7.
1997: Galanis E; Litzow M R; Tefferi A; Scott J P
Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone marrow transplantation.
Bone marrow transplantation 1997;20(8):695-6.
1997: Solberg L A; Tefferi A; Oles K J; Tarach J S; Petitt R M; Forstrom L A; Silverstein M N
The effects of anagrelide on human megakaryocytopoiesis.
British journal of haematology 1997;99(1):174-80.
1997: Elliott M A; Tefferi A; Marshall W F; Lacy M Q
Disseminated nocardiosis after allogeneic bone marrow transplantation.
Bone marrow transplantation 1997;20(5):425-6.
1997: Gertz M A; Lacy M Q; Inwards D J; Pineda A A; Chen M G; Gastineau D A; Tefferi A; Kyle R A; Litzow M R
Factors influencing platelet recovery after blood cell transplantation in multiple myeloma.
Bone marrow transplantation 1997;20(5):375-80.
1997: Fonseca R; Tefferi A; Strickler J G
Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report.
American journal of hematology 1997;55(3):148-55.
1997: Tefferi A; Bartholmai B J; Witzig T E; Jenkins R B; Li C Y; Hanson C A; Mesa R A; Phyliky R L
Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 1997;95(2):173-7.
1997: Tefferi A; Litzow M R; Noel P; Dewald G W
Chronic granulocytic leukemia: recent information on pathogenesis, diagnosis, and disease monitoring.
Mayo Clinic proceedings. Mayo Clinic 1997;72(5):445-52.
1997: Tefferi A; Elliott M A; Solberg L A; Silverstein M N
New drugs in essential thrombocythemia and polycythemia vera.
Blood reviews 1997;11(1):1-7.
1997: Fonseca R; Tefferi A
Practical aspects in the diagnosis and management of aplastic anemia.
The American journal of the medical sciences 1997;313(3):159-69.
1997: Tefferi A; Hanson C A; Kurtin P J; Katzmann J A; Dalton R J; Nichols W L
Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells.
British journal of haematology 1997;96(4):850-3.
1997: Tefferi A; Li C Y
Bone marrow granulomas associated with chronic natural killer cell lymphocytosis.
American journal of hematology 1997;54(3):258-62.
1997: Elliott M A; Tefferi A
Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
Seminars in thrombosis and hemostasis 1997;23(5):463-72.
1997: Tefferi A; Silverstein M N; Petitt R M; Mesa R A; Solberg L A
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Seminars in thrombosis and hemostasis 1997;23(4):379-83.
1997: Tefferi A; Silverstein M N
Agnogenic myeloid metaplasia.
Cancer investigation 1997;15(2):177-9.
1996: Tefferi A; Bartholmai B J; Witzig T E; Li C Y; Hanson C A; Phyliky R L
Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia.
American journal of clinical pathology 1996;106(4):457-61.
1996: Tefferi A; Silverstein M N
Current perspective in agnogenic myeloid metaplasia.
Leukemia & lymphoma 1996;22 Suppl 1():169-71.
1996: Tefferi A; Grendahl D C
Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.
American journal of hematology 1996;52(3):231-3.
1996: Okuno S H; Tefferi A; Hanson C A; Katzmann J A; Li C Y; Witzig T E
Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells.
British journal of haematology 1996;93(4):810-2.
1996: Bible K C; Tefferi A
Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis.
British journal of haematology 1996;93(2):406-8.
1996: Lacy M Q; Kurtin P J; Tefferi A
Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.
Blood 1996;87(7):3000-6.
1996: Rusnak F; Beressi A H; Haddy A; Tefferi A
Calcineurin protein phosphatase activity in peripheral blood lymphocytes.
Bone marrow transplantation 1996;17(3):309-13.
1996: Tefferi A
Chronic natural killer cell lymphocytosis.
Leukemia & lymphoma 1996;20(3-4):245-8.
1996: Fairbanks V F; Klee G G; Wiseman G A; Hoyer J D; Tefferi A; Petitt R M; Silverstein M N
Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods.
Blood cells, molecules & diseases 1996;22(2):169-86; discussion 186a-186g.
1995: Bartlett R P; Greipp P R; Tefferi A; Cupps R E; Mullan B P; Trastek V F
Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion.
Mayo Clinic proceedings. Mayo Clinic 1995;70(12):1161-4.
1995: Letendre L; Noel P; Tefferi A; Solberg L A; Gastineau D A; Hoagland H C
Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
American journal of clinical oncology 1995;18(5):382-4.
1995: Tefferi A; Schad C R; Pruthi R K; Ahmann G J; Spurbeck J L; Dewald G W
Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia.
Cancer genetics and cytogenetics 1995;83(1):61-4.
1995: Tefferi A; Silverstein M N; Hoagland H C
Primary thrombocythemia.
Seminars in oncology 1995;22(4):334-40.
1995: Tefferi A; Silverstein M N; Noël P
Agnogenic myeloid metaplasia.
Seminars in oncology 1995;22(4):327-33.
1995: Beressi A H; Tefferi A; Silverstein M N; Petitt R M; Hoagland H C
Outcome analysis of 34 pregnancies in women with essential thrombocythemia.
Archives of internal medicine 1995;155(11):1217-22.
1994: Tefferi A; Ho T C; Ahmann G J; Katzmann J A; Greipp P R
Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis.
The American journal of medicine 1994;97(4):374-8.
1994: Tefferi A; Colgan J P; Solberg L A
Acute porphyrias: diagnosis and management.
Mayo Clinic proceedings. Mayo Clinic 1994;69(10):991-5.
1994: Ho T C; Tefferi A; Su J Q; Litzow M R; Hoagland H C; Noël P
Acute lymphocytic leukemia in adults: a retrospective study and analysis of current management options.
Mayo Clinic proceedings. Mayo Clinic 1994;69(10):937-48.
1994: Tefferi A; Li C Y; Witzig T E; Dhodapkar M V; Okuno S H; Phyliky R L
Chronic natural killer cell lymphocytosis: a descriptive clinical study.
Blood 1994;84(8):2721-5.
1994: Dhodapkar M V; Li C Y; Lust J A; Tefferi A; Phyliky R L
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
Blood 1994;84(5):1620-7.
1994: Tefferi A; Barrett S M; Silverstein M N; Nagorney D M
Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia.
American journal of hematology 1994;46(4):325-8.
1994: Tefferi A; Mathew P; Noël P
The 5q- syndrome: a scientific and clinical update.
Leukemia & lymphoma 1994;14(5-6):375-8.
1994: Tefferi A; Hoagland H C
Issues in the diagnosis and management of essential thrombocythemia.
Mayo Clinic proceedings. Mayo Clinic 1994;69(7):651-5.
1994: Tefferi A; Solberg L A; Ellefson R D
Porphyrias: clinical evaluation and interpretation of laboratory tests.
Mayo Clinic proceedings. Mayo Clinic 1994;69(3):289-90.
1994: Tefferi A; Witzig T E; Reid J M; Li C Y; Ames M M
Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(3):569-74.
1994: Pruthi R K; Tefferi A
Pernicious anemia revisited.
Mayo Clinic proceedings. Mayo Clinic 1994;69(2):144-50.
1994: Tiede D J; Tefferi A; Kochhar R; Thompson G B; Hay I D
Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking.
Cancer 1994;73(3):702-5.
1994: Dhodapkar M; Goldberg S L; Tefferi A; Gertz M A
Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion.
American journal of hematology 1994;45(2):187-8.
1993: Tefferi A; Silverstein M N; Plumhoff E A; Reid J M; Ames M M
Suramin toxicity and efficacy in agnogenic myeloid metaplasia.
Journal of the National Cancer Institute 1993;85(18):1520-2.
1993: Dhodapkar M; Tefferi A; Su J; Phyliky R L
Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(8):1232-5.
1993: Noël P; Tefferi A; Pierre R V; Jenkins R B; Dewald G W
Karyotypic analysis in primary myelodysplastic syndromes.
Blood reviews 1993;7(1):10-8.
1993: Mathew P; Tefferi A; Dewald G W; Goldberg S L; Su J; Hoagland H C; Noel P
The 5q- syndrome: a single-institution study of 43 consecutive patients.
Blood 1993;81(4):1040-5.
1992: Goldberg S L; Tefferi A; Rummans T A; Chen M G; Solberg L A; Noël P
Post-irradiation somnolence syndrome in an adult patient following allogeneic bone marrow transplantation.
Bone marrow transplantation 1992;9(6):499-501.
1992: Tefferi A; Phyliky R L
A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities.
Mayo Clinic proceedings. Mayo Clinic 1992;67(5):457-61.
1992: Tefferi A; Greipp P R; Leibson P J; Thibodeau S N
Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(5):477-80.
1992: Tefferi A; Phyliky R L
A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis.
Mayo Clinic proceedings. Mayo Clinic 1992;67(4):349-53.
1992: Graham D L; Tefferi A; Letendre L; Gastineau D A; Hoagland H C; Noël P
Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia.
Mayo Clinic proceedings. Mayo Clinic 1992;67(2):123-7.
1990: Tefferi A; Zellers R A; Banks P M; Therneau T M; Colgan J P
Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(12):1959-65.
1990: Tefferi A; Bren G D; Wagner K V; Schaid D J; Ash R C; Thibodeau S N
The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(12):839-42.
1990: Tefferi A; Thibodeau S N; Solberg L A
Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms.
Blood 1990;75(9):1770-3.
1990: Solberg L A; Oles K J; Kimlinger T K; Tefferi A; Katzmann J A; Li C Y
A new murine monoclonal antibody for the diagnosis of erythroleukemia.
American journal of clinical pathology 1990;93(3):387-90.
1990: Tefferi A; Nichols W L; Bowie E J
Circulating heparin-like anticoagulants: report of five consecutive cases and a review.
The American journal of medicine 1990;88(2):184-8.
1989: Tefferi A; Hoagland H C; Therneau T M; Pierre R V
Chronic myelomonocytic leukemia: natural history and prognostic determinants.
Mayo Clinic proceedings. Mayo Clinic 1989;64(10):1246-54.
1989: Tefferi A; Li C Y; Phyliky R L
Correlation of clinical outcome with the degree of surface immunoglobulin (sIg) expression in B-cell chronic lymphocytic leukemia.
American journal of clinical pathology 1989;92(1):82-5.
1989: Tefferi A; Solberg L A; Petitt R M; Willis L G
Adult-onset cyclic bicytopenia: a case report and review of treatment of cyclic hematopoiesis.
American journal of hematology 1989;30(3):181-5.
1988: Tefferi A; Li C Y; Phyliky R L
Role of immunotyping in chronic lymphocytosis: review of the natural history of the condition in 145 adult patients.
Mayo Clinic proceedings. Mayo Clinic 1988;63(8):801-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Ayalew Tefferi

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Physiology

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Ayalew Tefferi (preview)

All Publications